Articles| Volume 5, ISSUE 6, P486-497, June 01, 2018
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

Summary

Background

Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population.

Methods

We did a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA. We included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater. Using a web-based randomisation system, we randomly assigned participants (1:1:2) to three different dose groups of MDMA plus psychotherapy: 30 mg (active control), 75 mg, or 125 mg. We masked investigators, independent outcome raters, and participants until after the primary endpoint. MDMA was administered orally in two 8-h sessions with concomitant manualised psychotherapy. The primary outcome was mean change in CAPS-IV total score from baseline to 1 month after the second experimental session. Participants in the 30 mg and 75 mg groups subsequently underwent three 100–125 mg MDMA-assisted psychotherapy sessions in an open-label crossover, and all participants were assessed 12 months after the last MDMA session. Safety was monitored through adverse events, spontaneously reported expected reactions, vital signs, and suicidal ideation and behaviour. This study is registered with ClinicalTrials.gov, number NCT01211405.

Findings

Between Nov 10, 2010, and Jan 29, 2015, 26 veterans and first responders met eligibility criteria and were randomly assigned to receive 30 mg (n=7), 75 mg (n=7), or 125 mg (n=12) of MDMA plus psychotherapy. At the primary endpoint, the 75 mg and 125 mg groups had significantly greater decreases in PTSD symptom severity (mean change CAPS-IV total scores of −58·3 [SD 9·8] and −44·3 [28·7]; p=0·001) than the 30 mg group (−11·4 [12·7]). Compared with the 30 mg group, Cohen's d effect sizes were large: 2·8 (95% CI 1·19–4·39) for the 75 mg group and 1·1 (0·04–2·08) for the 125 mg group. In the open-label crossover with full-dose MDMA (100–125 mg), PTSD symptom severity significantly decreased in the group that had previously received 30 mg (p=0·01), whereas no further significant decreases were observed in the group that previously achieved a large response after 75 mg doses in the blinded segment (p=0·81). PTSD symptoms were significantly reduced at the 12-month follow-up compared with baseline after all groups had full-dose MDMA (mean CAPS-IV total score of 38·8 [SD 28·1] vs 87·1 [16·1]; p<0·0001). 85 adverse events were reported by 20 participants. Of these adverse events, four (5%) were serious: three were deemed unrelated and one possibly related to study drug treatment.

Interpretation

Active doses (75 mg and 125 mg) of MDMA with adjunctive psychotherapy in a controlled setting were effective and well tolerated in reducing PTSD symptoms in veterans and first responders.

Funding

Multidisciplinary Association for Psychedelic Studies.
To read this article in full you will need to make a payment
Purchase one-time access
Or purchase The Lancet Choice
Access any 5 articles from the Lancet Family of journals
Subscribe to The Lancet Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Institutional Access: Sign in to ScienceDirect

References

  1. 1.
    • Hoge CW
    • Castro CA
    • Messer SC
    • McGurk D
    • Cotting DI
    • Koffman RL
    Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care.
    N Engl J Med. 2004; 351: 13-22
  2. 2.
    • Javidi H
    • Yadollahie M
    Post-traumatic stress disorder.
    Int J Occup Environ Med. 2012; 3: 2-9
  3. 3.
    • Shea MT
    • Vujanovic AA
    • Mansfield AK
    • Sevin E
    • Liu F
    Posttraumatic stress disorder symptoms and functional impairment among OEF and OIF national guard and reserve veterans.
    J Trauma Stress. 2010; 23: 100-107
  4. 4.
    • Sareen J
    • Cox BJ
    • Stein MB
    • Afifi TO
    • Fleet C
    • Asmundson GJ
    Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample.
    Psychosom Med. 2007; 69: 242-248
  5. 5.
    • Krystal JH
    • Davis LL
    • Neylan TC
    • et al.
    It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group.
    Biol Psychiatry. 2017; 82: e51-e59
  6. 6.
    • Lee DJ
    • Schnitzlein CW
    • Wolf JP
    • Vythilingam M
    • Rasmusson AM
    • Hoge CW
    Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments.
    Depress Anxiety. 2016; 33: 792-806
  7. 7.
    • Steenkamp MM
    • Litz BT
    • Hoge CW
    • Marmar CR
    Psychotherapy for military-related PTSD: a review of randomized clinical trials.
    JAMA. 2015; 314: 489-500
  8. 8.
    • Goetter EM
    • Bui E
    • Ojserkis RA
    • Zakarian RJ
    • Brendel RW
    • Simon NM
    A systematic review of dropout from psychotherapy for posttraumatic stress disorder among Iraq and Afghanistan combat veterans.
    J Trauma Stress. 2015; 28: 401-409
  9. 9.
    • Mott JM
    • Mondragon S
    • Hundt NE
    • Beason-Smith M
    • Grady RH
    • Teng EJ
    Characteristics of US veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD.
    J Trauma Stress. 2014; 27: 265-273
  10. 10.
    • Feduccia AA
    • Mithoefer MC
    • Jerome L
    • Holland J
    • Emerson A
    • Doblin R
    Response to the consensus statement of the PTSD Psychopharmacology Working Group.
    Biol Psychiatry. 2017; (published online Nov 23.)
  11. 11.
    • Feduccia AA
    • Holland J
    • Mithoefer MC
    Progress and promise for the MDMA drug development program.
    Psychopharmacology. 2018; 235: 561-571
  12. 12.
    • Mithoefer MC
    • Wagner MT
    • Mithoefer AT
    • Jerome L
    • Doblin R
    The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
    J Psychopharmacol. 2011; 25: 439-452
  13. 13.
    • Oehen P
    • Traber R
    • Widmer V
    • Schnyder U
    A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD).
    J Psychopharmacol. 2013; 27: 40-52
  14. 14.
    • Mithoefer MC
    • Wagner MT
    • Mithoefer AT
    • et al.
    Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
    J Psychopharmacol. 2013; 27: 28-39
  15. 15.
    • Blake DD
    • Weathers FW
    • Nagy LM
    • et al.
    A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1.
    Behav Ther. 1990; 13: 187-188
  16. 16.
    • First MB
    • Spitzer RL
    • Gibbon M
    • Williams JBW
    Structured Clinical Interview for DSM-IV Axis I Disorders—patient edition (SCID-I/P, version 2.0, 4/97 revision).
    Biometrics Research Department and New York State Psychiatric Institute, New York1997
  17. 17.
    • Mithoefer M
    A manual for MDMA-assisted psychotherapy in the treatment of PTSD (version 8).
  18. 18.
    • Beck AT
    • Steer RA
    • Ball R
    • Ranieri W
    Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients.
    J Pers Assess. 1996; 67: 588-597
  19. 19.
    • Buysse DJ
    • Reynolds 3rd, CF
    • Monk TH
    • Berman SR
    • Kupfer DJ
    The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.
    Psychiatry Res. 1989; 28: 193-213
  20. 20.
    • Tedeschi RG
    • Calhoun LG
    The Posttraumatic Growth Inventory: measuring the positive legacy of trauma.
    J Trauma Stress. 1996; 9: 455-471
  21. 21.
    • Costa PT
    • Macrae RR
    The NEO personality inventory manual.
    Psychological Assessment Resources, Odessa, FL1985
  22. 22.
    • Carlson EB
    • Putnam FW
    An update on the Dissociative Experiences Scale.
    Dissociation. 1993; 6: 16-27
  23. 23.
    • American Psychiatric Association
    Diagnostic and statistical manual of mental disorders.
    4th edition. American Psychiatric Association, Arlington, VA2000
  24. 24.
    • Posner K
    • Brown GK
    • Stanley B
    • et al.
    The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.
    Am J Psychiatry. 2011; 168: 1266-1277
  25. 25.
    • Talbert FS
    • Braswell LC
    • Albrecht JW
    • Hyer LA
    • Boudewyns PA
    NEO-PI profiles in PTSD as a function of trauma level.
    J Clin Psychol. 1993; 49: 663-669
  26. 26.
    • MacLean KA
    • Johnson MW
    • Griffiths RR
    Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    J Psychopharmacol. 2011; 25: 1453-1461
  27. 27.
    • Wagner MT
    • Mithoefer MC
    • Mithoefer AT
    • et al.
    Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy.
    J Psychopharmacol. 2017; 31: 967-974
  28. 28.
    • Carhart-Harris RL
    • Murphy K
    • Leech R
    • et al.
    The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity.
    Biol Psychiatry. 2015; 78: 554-562
  29. 29.
    • Gamma A
    • Buck A
    • Berthold T
    • Liechti ME
    • Vollenweider FX
    3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans.
    Neuropsychopharmacology. 2000; 23: 388-395
  30. 30.
    • Walpola IC
    • Nest T
    • Roseman L
    • et al.
    Altered insula connectivity under MDMA.
    Neuropsychopharmacology. 2017; 42: 2152-2162
  31. 31.
    • Feduccia AA
    • Mithoefe MC
    MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?.
    Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84: 221-228
  32. 32.
    • Sripada RK
    • King AP
    • Garfinkel SN
    • et al.
    Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder.
    J Psychiatry Neurosci. 2012; 37: 241-249
  33. 33.
    • Fredman SJ
    • Monson CM
    • Adair KC
    Implementing cognitive-behavioral conjoint therapy for PTSD with the newest generation of veterans and their partners.
    Cogn Behav Pract. 2011; 18: 120-130
  34. 34.
    • Cisler JM
    • Steele JS
    • Lenow JK
    • et al.
    Functional reorganization of neural networks during repeated exposure to the traumatic memory in posttraumatic stress disorder: an exploratory fMRI study.
    J Psychiatr Res. 2014; 48: 47-55

Linked Articles